The Drug Enforcement Administration (DEA) published its formal proposal for cannabis rescheduling, officially putting what is set to be the most meaningful overhaul of cannabis regulation in 50-years into motion.
Tuesday’s (May 21, 2024) publication of the proposal means that the 60-day comment period is now open, giving commenters until July 22 to submit their comments electronically. Interested parties may also file a request for a hearing on or before June 20.
In its proposal, the DEA says that the Attorney General has determined that cannabis does not appear to meet the elements of a Schedule II drug, including high potential for abuse and the likelihood of severe physiological or physical dependence.
It also notes that synthetically produced cannabis would not be included in the reclassification, which is outside of the Controlled Substances Act’s (CSA) definition, and will therefore remain a Schedule I substance.
Comments are now being sought from ‘all interested persons’, and are expected to include the general public, stakeholders in the medical and scientific community, legal and regulatory experts, industry representatives, advocacy groups, and government agencies.
Specifically, the proposal calls for comments relating to the economic analysis of the proposed changes and encourages commenters to provide detailed descriptions, especially concerning the impact on small entities, and to support their comments with empirical data.
In this vein, the DOJ says it ‘acknowledges that there may be large impacts related to Federal taxes and research and development investment for the pharmaceutical industry, among other things.’
Furthermore, it states that the Attorney General, Merick Garland, must consider compliance with international treaty obligations, including the Single Convention, which requires signatories to ‘maintain various provisions related to the drugs’ covered by the treaty.
While no prospective timeline was given for how long the comments will take to consider, or whether a final hearing will take place, sources speaking to Business of Cannabis have suggested the change could be finalised by Q1 2025.
DEA & DOJ Officially Submit Proposal for Cannabis Rescheduling, Setting Comment Period in Motion
The Drug Enforcement Administration (DEA) published its formal proposal for cannabis rescheduling, officially putting what is set to be the most meaningful overhaul of cannabis regulation in 50-years into motion.
Tuesday’s (May 21, 2024) publication of the proposal means that the 60-day comment period is now open, giving commenters until July 22 to submit their comments electronically. Interested parties may also file a request for a hearing on or before June 20.
In its proposal, the DEA says that the Attorney General has determined that cannabis does not appear to meet the elements of a Schedule II drug, including high potential for abuse and the likelihood of severe physiological or physical dependence.
It also notes that synthetically produced cannabis would not be included in the reclassification, which is outside of the Controlled Substances Act’s (CSA) definition, and will therefore remain a Schedule I substance.
Comments are now being sought from ‘all interested persons’, and are expected to include the general public, stakeholders in the medical and scientific community, legal and regulatory experts, industry representatives, advocacy groups, and government agencies.
Specifically, the proposal calls for comments relating to the economic analysis of the proposed changes and encourages commenters to provide detailed descriptions, especially concerning the impact on small entities, and to support their comments with empirical data.
In this vein, the DOJ says it ‘acknowledges that there may be large impacts related to Federal taxes and research and development investment for the pharmaceutical industry, among other things.’
Furthermore, it states that the Attorney General, Merick Garland, must consider compliance with international treaty obligations, including the Single Convention, which requires signatories to ‘maintain various provisions related to the drugs’ covered by the treaty.
While no prospective timeline was given for how long the comments will take to consider, or whether a final hearing will take place, sources speaking to Business of Cannabis have suggested the change could be finalised by Q1 2025.
Could Rescheduling Finally Bring Institutional Investment in to Cannabis?
Next PostAkanda Implements 2nd Stock Split Amid Debt Woes, DanCann Pharma Earnings Fall Due to Strategy Change, & More From Celadon
Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, they have researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Related Posts
Related Posts
Federal Agencies ‘May Lack Resources’ to Enforce US Hemp Ban, Congressional Researchers Warn
The incoming changes to hemp classification in the US are already facing major issues, with the Government’s own Congressional Research...
Medicare CBD Coverage Proposed, But Federal Ban Threatens Entire Industry
Cannabis stocks enjoyed another spike last week following reports that the Centers for Medicare & Medicaid Services is preparing to...
UK Court Throws Out CBD Case Over Improper Testing, but Operators ‘More Vulnerable Than Ever’
Bundesrat Backs Tighter Cannabis Prescribing Rules, Rejects Mail-Order Penalties
EU ‘Intoxicating Hemp’ Review Highlights Major Knowledge Gaps Behind Blanket Bans
Trump Ends Intoxicating Hemp Era, But Unintended Victims and Repeal Efforts Signal Turbulent Year Ahead
CONNECT
Related Posts
Related Posts
Federal Agencies ‘May Lack Resources’ to Enforce US Hemp Ban, Congressional Researchers Warn
The incoming changes to hemp classification in the US are already facing major issues, with the Government’s own Congressional Research...
Medicare CBD Coverage Proposed, But Federal Ban Threatens Entire Industry
Cannabis stocks enjoyed another spike last week following reports that the Centers for Medicare & Medicaid Services is preparing to...
UK Court Throws Out CBD Case Over Improper Testing, but Operators ‘More Vulnerable Than Ever’
A UK Crown Court has thrown out criminal charges against CBD hemp flower importers after ruling that police mishandled evidence...
Bundesrat Backs Tighter Cannabis Prescribing Rules, Rejects Mail-Order Penalties
Germany's Bundesrat voted on November 21 to support key restrictions on medical cannabis prescribing and distribution, while rejecting proposals to...
EU ‘Intoxicating Hemp’ Review Highlights Major Knowledge Gaps Behind Blanket Bans
Last week, the US government voted to impose a blanket ban on all so-called ‘intoxicating hemp’ substances, ending what has...
Recent Posts
Related Posts
Drug War 2.0 Puts International Cannabis Reform at Risk
The United States is intensifying its controversial overseas ‘war on drugs’ even as a prolonged government shutdown paralyses domestic policy,...
Manufactured Optimism: Why Trump Can’t ‘Just Wave a Magic Wand’ and Reschedule Cannabis
There is a frustrating misimpression circulating in the cannabis community regarding rescheduling. Many headlines state that Trump is considering finishing...
Pressure Builds on Trump Administration to take Definitive Stance on Cannabis Rescheduling
Pressure is building on the Trump administration from parties on both sides of the aisle to take a definitive stance...
No EU Monograph for Cannabis Flowers Over ‘Lack of Evidence’ as New GACP Rules Loom
The Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency (EMA) published a draft opinion on July 09,...
What Cannabis Leaders Can Learn from Olympic Champions
In this special edition of the Business of Cannabis Podcast, Tim Kirby, CEO of Releaf, sits down with Professor Chris...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags